Glioblastoma tackled with oncolytic virus

Access through your institution Buy or subscribe A first-in-human trial indicates that treatment with an oncolytic virus is associated with increased survival in people with glioblastoma. In

the phase I trial, 41 people with recurrent glioblastoma received intra-tumoural injection of an oncolytic herpes simplex virus (HSV) known as CAN-3110. The treatment produced an

inflammatory tumour microenvironment that was favourable for immune responses against the tumour and was associated with increased survival time, particularly among people with HSV1

seropositivity. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get

Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only

$17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout

ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES ORIGINAL ARTICLE * Ling, A. L. et al. Clinical trial

links oncolytic immunoactivation to survival in glioblastoma. _Nature_ https://doi.org/10.1038/s41586-023-06623-2 (2023) Article  PubMed  PubMed Central  Google Scholar  Download references

AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Nature Reviews Neurology http://www.nature.com/nrneurol/ Ian Fyfe Authors * Ian Fyfe View author publications You can also search for this

author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Ian Fyfe. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Fyfe, I. Glioblastoma

tackled with oncolytic virus. _Nat Rev Neurol_ 19, 711 (2023). https://doi.org/10.1038/s41582-023-00903-1 Download citation * Published: 08 November 2023 * Issue Date: December 2023 * DOI:

https://doi.org/10.1038/s41582-023-00903-1 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative